A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma

Huijie Yang†, Weiwen Zhang†, Jin Ding†, Jingyi Hu†, Yi Sun‡, Weijun Peng§, Yi Chu¶, Lingxiang Xie†, Zhibing Mei§, Zhuo Shao∥ and Yang Xiao∥

†National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China, ‡Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China, §Department of Integrated Traditional Chinese and Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, China, ¶Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, China, ∥Department of Anorectal Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China, ∥Anorectal Disease Institute of Shuguang Hospital, Shanghai, China, Department of General Surgery, Changhai Hospital, Naval Medical University, Shanghai, China

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor of the digestive system. Its grim prognosis is mainly attributed to the lack of means for early diagnosis and poor response to treatments. Genomic instability is shown to be an important cancer feature and prognostic factor, and its pattern and extent may be associated with poor treatment outcomes in PDAC. Recently, it has been reported that long non-coding RNAs (lncRNAs) play a key role in maintaining genomic instability. However, the identification and clinical significance of genomic instability-related lncRNAs in PDAC have not been fully elucidated.

Methods: Genomic instability-derived lncRNA signature (GILncSig) was constructed based on the results of multiple regression analysis combined with genomic instability-associated lncRNAs and its predictive power was verified by the Kaplan-Meier method. And real-time quantitative polymerase chain reaction (qRT-PCR) was used for simple validation in human cancers and their adjacent non-cancerous tissues. In addition, the correlation between GILncSig and tumor microenvironment (TME) and epithelial-mesenchymal transition (EMT) was investigated by Pearson correlation analysis.

Results: The computational framework identified 206 lncRNAs associated with genomic instability in PDAC and was subsequently used to construct a genome instability-derived five IncRNA-based gene signature. Afterwards, we successfully validated its prognostic capacity in The Cancer Genome Atlas (TCGA) cohort. In addition, via careful examination of the transcriptome
expression profile of PDAC patients, we discovered that GIILncSig is associated with EMT and an adaptive immunity deficient immune profile within TME.

**Conclusions:** Our study established a genomic instability-associated IncRNAs-derived model (GIILncSig) for prognosis prediction in patients with PDAC, and revealed the potential functional regulatory role of GIILncSig.

**KEYWORDS**
long non-coding RNAs, genome instability, tumor microenvironment, pancreatic ductal adenocarcinoma, epithelial-mesenchymal transition

**Highlights**
We established a mutational hypothesis-derived computational framework for identifying genomic instability-associated IncRNAs in PDAC and constructed IncRNA signatures to better predict the prognosis of PDAC patients.

In addition, we investigated the immune profile characteristics and potential functional regulatory effects associated with IncRNA signatures, and we found that GIILncSig is associated with EMT as well as adaptive immune deficiency immune profiles within the TME.

Our findings may improve prognostic prediction methods for PDAC and provide potential guidance for precise immunotherapy in the future.

**1 Introduction**
Pancreatic ductal adenocarcinoma is one of the aggressive solid malignancies, and the rising incidence of PDAC is expected to be the second leading cause of cancer-related mortality by 2030 (1, 2). However, only 10% to 20% of pancreatic cancer patients have the chance of surgery as most patients have distant metastasis of the lesion at the time of diagnosis (3). Moreover, even for patients with the chance of surgery, they still possessed a rather low 5-year survival rate and over 80% postoperative recurrence rate (4). Despite recent advances in pancreatic cancer research, there has been no significant reduction in overall mortality and morbidity (5), because of the lack of specific symptoms and reliable biomarkers for early diagnosis, as well as poor response to treatment due to tumor dissemination. Therefore, there is an urgent need to develop new and effective strategies that can predict prognosis and improve therapeutic targeting to achieve personalized treatment.

Genomic instability is shown to be an important cancer characteristic as well as a prognostic factor, and the pattern and degree of which is associated with tumor progression and recurrence (6, 7). Although the specific molecular mechanisms affecting genomic instability are not fully understood yet. Recently, long non-coding RNAs, a group of non-coding RNAs with more than 200 nucleotides in length (8, 9), are considered to have the potential to quantitatively measure genomic instability (10–16). Interestingly, quite a few previous studies have reported a variety of IncRNAs that may contribute to the carcinogenesis and development of PDAC (17–19). Therefore, we believe that IncRNAs may represent a new class of PDAC biomarkers and therapeutic targets. Likewise, genomic-instability related IncRNAs were successfully used to build prognostic models for other types of cancer, including breast cancer, gastric cancer, and glioblastoma (20–22).

Besides, it is widely believed that studies targeting the crosstalk between tumor cells and the TME will shed light on the novel treatment measures for pancreatic cancer. Immune checkpoint inhibitors have been reported to show durable clinical benefits in many malignancies (23). However, we found that the effect of this class of drugs was not satisfactory in PDAC, which may be ascribed to the distinct TME profile. Cancer often creates a favorable TME for its successful growth by disrupting the immune, vascular, and connective tissue components of the stroma that counter the physiological responses to damage. Among them, the intensive interstitial and highly immunosuppressive environment is a special weapon for PDAC (24–26). At the same time, the degree of T-cell infiltration in PDAC patients correlates with disease progression, and patients with a higher level of T-cell infiltration are generally more sensitive to immunotherapy (27, 28).

In this study, we employed bioinformatics and statistics methods, combined with the IncRNA expression profile of tumor genomes, the somatic mutation profile of tumor genomes, and the clinical features of PDCA patients to establish a genomic-instability associated IncRNA-derived signature called GIILncSig. The GIILncSig risk score was calculated as a surrogate tool for assessing the likelihood of survival in patients with PDCA, and its prognostic value was
further validated by survival analysis. Moreover, to understand the concomitant functional regulatory effects of GILncSig on the transcriptomic expression profiles, we conducted graph-based clustering analysis, differential expression analysis and functional enrichment analysis to in-depth analyze transcriptomic expression characteristics associated with GILncSig, revealing that GILncSig is related to EMT. In addition, we investigated the IncRNA signature associated immune profile characteristics and potential functional regulatory effects. We believe that our findings may improve the prognostic prediction method of PDAC and provide potential guidance for future precise immunotherapy.

2 Materials and methods

2.1 Data collection

RNA-seq expression data, clinical features, clinicopathological characteristics, survival information, and somatic mutation information of patients with pancreatic ductal adenocarcinoma were collected from TCGA database (https://portal.gdc.cancer.gov/). LncRNA expression data were downloaded from the TANRIC database (http://bioinformatics.mdanderson.org/main/TANRIC: Overview, version 1.0.6). Due to the missing values in the follow-up dataset, 7 patients from the TCGA cohort were excluded, and the remaining 171 samples were retained for further study. A flow chart of the inclusion and exclusion criteria for patient data is presented in Supplementary Figure 1. The patients with PDAC used in this study were randomly divided into the following two patient sets after matching for gender, age, and tumor stage: training set (n = 87) and test set (n = 84), with no significant differences in clinical features between these two sets. The training set was used to identify prognostic IncRNA signature and build prognostic risk model, while the testing set was used to independently validate the performance of the prognostic risk model.

2.2 Identification of genome instability-associated IncRNAs

As described in the previous study, a mutator hypothesis-derived computational frame combining IncRNA expression profiles and somatic mutation profiles in a tumor genome was used to identify genome instability-associated IncRNAs (29). In brief, the cumulative number of somatic mutations was first calculated for each pancreatic cancer patient and sorted in descending order. Next, the first 25% and last 25% of patients were defined as genomic instability (GU) and genomic stability (GS) sample groups, respectively. Finally, the expression profiles of IncRNAs of the GU and GS groups were compared using the significance analysis of microarrays (SAM) method, and the differentially expressed IncRNAs between these two groups (fold change > 1.5 or < 0.67 and false discovery rate (FDR) adjusted P< 0.05) were defined as genome instability-associated IncRNAs (29).

2.3 Functional enrichment analysis

To understand the potential functional regulation exerted by the identified genome instability-associated IncRNAs, an exploratory graph-based clustering analysis using the Louvain clustering algorithm was performed on the entire TCGA dataset, identifying three distinct clusters in all pancreatic ductal adenocarcinoma patients. Functional enrichment analysis of the extracted top 50 differentially expressed genes and top 30 differentially expressed transcription factors (TFs) from each cluster was conducted using the Metascape webtool (www.metascape.org) to determine significantly enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (30). As a result, we found that cluster 1 was implicated in EMT.

2.4 Statistical analysis

We used univariate and multivariate Cox proportional hazard regression analysis to evaluate the association between the expression level of genome instability-associated IncRNA and overall survival. According to the coefficients from the multivariate regression analysis and the expression levels of prognostic genome instability-associated IncRNAs, a genome instability-derived IncRNA signature for outcome prediction was constructed as follows:

$$ GILncSig = \sum_{i=1}^{n} \text{coef}(\text{IncRNA}_i) \cdot \exp(\text{IncRNA}_i),$$

In this equation, GILncSig, the established prognostic risk score for patients with pancreatic ductal adenocarcinoma, is calculated by adding up the product of the coefficient of each IncRNA derived from the multivariate regression analysis and its expression level. The median score of the patients in the training set was used as the risk cutoff value to classify patients into either a high-risk group with high GILncSig or a low-risk group with low GILncSig.

Median survival and survival rates were calculated for each prognostic risk group using the Kaplan-Meier method, and the log-rank test was used to assess the survival difference between the high-risk and low-risk groups at the 5% significance level. The independence of GILncSig from other key clinical factors was clarified by multivariate Cox regression and stratification analysis. The performance of GILncSig was also assessed by receiver operating characteristic (ROC) curves. Unsupervised hierarchical clustering analysis for the identification of GU-like and GS-like groups was performed using Euclidean distance and
Ward’s linkage method, whereas unsupervised hierarchical clustering analysis for the investigation of the potential functional regulatory role of GILncSig was performed using Louvain clustering algorithm and graph-based clustering method. The association between GILncSig risk groups and cluster 1 was consolidated via Pearson correlation analysis between GILncSig risk score and EMT signature score. All statistical analyses were performed using R-version 3.6.

2.5 Gene set enrichment analysis

Gene set enrichment analysis was carried out using two EMT signatures constructed from previously reported literature (31, 32). Enriched-ness of gene expression in each gene set of patients was defined by a signature score calculated through RVISION package.

2.6 Estimated the immune profile of tumor microenvironment

To better understand the GILncSig-related immune landscape, we used the CIBERSORT algorithm (https://cibersort.stanford.edu/index.php) combined with LM22 to estimate the abundances of immune cell subsets within the TME in each patient, as designed in the previous study (33). An empirical P-value for the deconvolution using Monte Carlo sampling was thereby produced, and cases with a resulting P-value < 0.05 were available for further analysis. We then estimated the Immune Score, namely the ratio of immune matrix components in the TME of each sample, by the ESTIMATE algorithm (34). The higher the Immune Score, the larger the ratio of the immune components in TME. Furthermore, the correlation between GILncSig risk scores and Immune Score was validated by Pearson correlation analysis.

2.7 Tissue specimens

Five formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma tumor specimens and their adjacent tissues were obtained from the pathology department of the hospital, and qRT-PCR was performed on these tissues. These patients met the following inclusion criteria: (1) Adult patients aged ≥ 18 years and ≤ 75 years, histologically (non-cytologically) diagnosed with PDAC; (2) Patients with stage I-III according to the 8th edition of the American Joint Committee on Cancer (AJCC) classification; (3) Patients with a life expectancy ≥ 3 months. The exclusion criteria were: (1) Patients diagnosed with other types of pancreatic malignant tumor or malignant tumor (s) of other tissues; (2) Patients with other severe concomitant disease or disorder such as heart, liver, or renal failure; (3) Patients having no adjacent non-cancerous tissue in the paraffin-embedded pancreatic tissue. This study was approved by the local Ethics Committee (Second Xiangya Hospital Ethics Committee) (approved no. 2020-465). The requirement for written informed consent was waived for the retrospective tissue samples included in the pancreatic ductal adenocarcinoma tumor specimens.

2.8 RNA isolation and qRT-PCR analysis

Total RNA was prepared using The ReliaPrep™ FFPE Total RNA Miniprep System (Promega) according to the manufacturer’s instructions. The concentration of the total RNA was detected by NanoDrop 2000 (Thermo Scientific™). Total RNA (1000 ng) was reverse transcribed into cDNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific™). The relative expression of target genes to the housekeeping gene GAPDH was determined by qRT-PCR using GoTaq® qPCR Master Mix (Promega). All primer sequences used in this study were listed in Supplementary Table 1. Analysis between the two groups was performed by an unpaired t-test; P < 0.05 was considered statistically significant.

3 Results

3.1 Identification of genomic instability-related lncRNAs in pancreatic cancer patients

3.1.1 Identification of genomic instability-related lncRNAs

The flowchart of the study is described in Supplementary Figure 2. To identify lncRNAs associated with genomic instability, we calculated the cumulative number of somatic mutations per patient and sorted them in ascending order. The top 25% (n = 40) and the last 25% (n = 43) of patients were assigned to GS-like and GU-like groups based on the cumulative number of somatic mutations. Next, a total number of 206 differentially expressed lncRNAs (labeled as DE lncRNAs) between GU-like and GS-like groups were identified based on the comparison of their lncRNA expression profiles (with the absolute value of logFC greater than 1 and FDR-adjusted P-value less than 0.05). Among them, 95 lncRNAs were upregulated and 111 lncRNAs were downregulated in the GU-like group.

3.1.2 Clustering analysis for patient classification

To classify all 178 TCGA patients into either GU-like or GS-like groups, unsupervised hierarchical clustering analysis was performed using 206 DE lncRNAs. As shown in Figure 1A, all 178 samples were clustered into two groups based on the
expression levels of the 206 DE lncRNAs. The GU-like group has significantly higher cumulative somatic mutation counts compared with the GS-like group (P < 0.001, Mann–Whitney U test; Figure 1B). Comparison of the expression level of UBQLN4 gene, a newly identified biomarker for genomic instability, reveals that the GU-like group has a significantly higher expression level of UBQLN4 compared with the GS-like group (P < 0.001, Mann–Whitney U test; Figure 1C).

3.2 Establishment of genomic instability-derived lncRNA signature and outcome prediction

3.2.1 Screening of prognostic-related lncRNAs using Cox proportional hazard regression analysis in the training set

To explore the potential prognostic values of 206 DE lncRNAs, 7 pancreatic cancer patients from the TCGA cohort were excluded due to missing values in their follow-up dataset. The remaining 171 pancreatic cancer patients were randomly split into 2 sets: training set (n = 87) and testing set (n = 84). Statistical comparison of key clinical features between the patients within the training set and the testing set revealed that no significant differences exist between patients in these 2 sets (Table 1). The training set will be used for the following procedures. To screen for lncRNAs that can be used as prognostic factors, univariate Cox proportional hazard regression analysis was first performed to determine if the expression level of each DE lncRNA is significantly associated with the prognosis, i.e., the overall survival (OS) of pancreatic cancer patients. As a result, 22 DE lncRNAs were identified (P < 0.05, Table 2). Next, these 22 candidate DE lncRNAs were subjected to multivariate Cox proportional hazards regression analysis with common clinical features such as age, gender, and tumor grade to further screen lncRNAs with prognostic ability independent of other lncRNAs. Subsequently, five lncRNAs (TM4SF1-AS1, CASC8, PRDM16-DT, LINC00996, AP000892.3, labeled siglncRNAs) were identified (P < 0.1, Table 3) as independent prognostic factors.

3.2.2 Construction of GILncSig and outcome prediction for the training set, testing set, and combined TCGA set

Afterward, a genomic instability-derived lncRNA signature was constructed based on the coefficients of the aforementioned multivariate Cox proportional hazard regression model and the expression level of siglncRNAs. The formula is as follows: GILncSig score = (0.2917 × expression level of TM4SF1-AS1) + (0.1665 × expression level of CASC8) + (-0.2782 × expression level of PRDM16-DT) + (-1.1024 × expression level of LINC00996) + (-1.0421 × expression level of AP000892.3). Of the GILncSig, the coefficient of lncRNA TM4SF1-AS1 and CASC8 were positive, suggesting that they are risk factors as their expressions were correlated with a poor prognosis, whereas the coefficient of lncRNA PRDM16-DT, LINC00996 and AP000892.3 were negative, suggesting that they are protective factors as their expressions were correlated with a better outcome. To predict the survival of pancreatic patients, the risk score for each patient in the training set was obtained through GILncSig. Using the median risk score (1.146) as the cut-off value, these patients were classified into two prognostic groups—either high-risk or low-risk groups. Kaplan-Meier analysis revealed that the survival outcomes of patients in the high-risk group are significantly worse than those in the low-risk group (median OS 1.46 years versus 4.12 years, P < 0.01, log-rank test; Figure 2A). The survival rate of the high-risk group was 18.6% at 3 years and that of the low-risk group was 54.3%. The area under curve (AUC) yielded by the time-dependent ROC curves analysis of GILncSig was 0.725 (Figure 2B). Similarly, the survival analysis and time-dependent ROC curves analysis were applied to the testing set and the combined TCGA cohort. For the testing set, Kaplan-Meier analysis revealed that the survival outcomes of patients in the high-risk group are significantly worse than those in the low-risk group (median OS 1.08 years versus 1.92 years, P = 0.04, log-rank test; Figure 2C). The survival rate of the high-risk group was 22.5% at 3 years and that of the low-risk group was 48.3%. The AUC yielded by the time-dependent ROC curves analysis of GILncSig was 0.727 (Figure 2D). For the combined TCGA cohort, Kaplan-Meier analysis revealed that the survival outcomes of patients in the high-risk group are significantly worse than those in the low-risk group (median OS 1.30 years versus 3.65 years, P < 0.01, log-rank test; Figure 2E). The survival rate of the high-risk group was 18.8% at 3 years and that of the low-risk group was 51.2%. The AUC yielded by the time-dependent ROC curves analysis of GILncSig was 0.721 (Figure 2F).

3.2.3 Verification of GILncSig as a valid prognostic factor independent of key clinical features

To clarify the independence of GILncSig from other clinical features, both univariate and multivariate Cox proportional hazard regression analysis were utilized. First, we preprocessed the data of patients in TCGA and excluded data with missing grades, stages, or ages. Next, univariate Cox proportional hazard regression analysis was carried out on GILncSig score and clinical features including score, age, gender, pathological stage, and tumor grade. As a result, GILncSig score, age, and tumor grade were identified as significant prognostic factors (P < 0.05, Table 4). Later, multivariate Cox proportional hazard regression analysis was performed among GILncSig score, age, and tumor grade. Finally, GILncSig and age retained their prognostic significance (P < 0.05, Table 5), which demonstrated that GILncSig could act as an independent prognostic factor. As age is significantly correlated with the overall survival of pancreatic patients, a stratification analysis is in need to reassure that the significantly different predicted survival
outcomes of the high-risk and low-risk groups determined by GILncSig were not attributed to age difference. To do so, we stratified patients in the TCGA set into a young-patient group (n = 90) and an old-patient group (n = 81) according to the median age (age = 65) of the whole TCGA cohort. Then, the GILncSig risk score for patients in each age group was calculated to further divide them into high-risk or low-risk groups. As shown in Figure 2, the high-risk group has significantly worse overall survival compared with the low-risk group in both the young-patient group (P < 0.001, log-rank test; Figure 2G) and old-patient group (P = 0.027, log-rank test; Figure 2H).

3.2.4 Alignment of GILncSig scores with somatic mutation and UBQLN4 gene expression patterns

We further explored the variation patterns of somatic mutation counts and UBQLN4 gene expression levels with increasing GILncSig scores to consolidate GILncSig's
### TABLE 1 Clinical information for three TCGA patients sets in this study.

| Covariates | Type | TCGA set | Training set | Testing set | P value |
|------------|------|----------|--------------|-------------|---------|
| Age        | <=65 | 90 (52.63%) | 50 (57.47%) | 40 (47.62%) | 0.2556  |
|            | >65  | 81 (47.37%) | 37 (42.53%) | 44 (52.38%) |         |
| Gender     | FEMALE | 78 (45.61%) | 40 (45.98%) | 38 (45.24%) | 1       |
|            | MALE  | 93 (54.39%) | 47 (54.02%) | 46 (54.76%) |         |
| Grade      | G1-2 | 120 (70.18%) | 63 (72.41%) | 57 (67.86%) | 0.467   |
|            | G3-4  | 49 (28.65%) | 22 (25.29%) | 27 (32.14%) |         |
|            | Unknown | 2 (1.17%) | 2 (2.3%) | 0 (0%) |         |
| Stage      | Stage I-II | 161 (94.15%) | 82 (94.25%) | 79 (94.05%) | 0.9743  |
|            | Stage III-IV | 7 (4.09%) | 3 (3.45%) | 4 (4.76%) |         |
|            | unknown | 3 (1.75%) | 2 (2.3%) | 1 (1.19%) |         |
| T          | T1-2 | 28 (16.37%) | 14 (16.09%) | 14 (16.67%) | 1       |
|            | T3-4 | 141 (82.46%) | 72 (82.76%) | 69 (82.14%) |         |
|            | unknown | 2 (1.17%) | 1 (1.15%) | 1 (1.19%) |         |
| M          | M0   | 77 (45.03%) | 39 (44.83%) | 38 (45.24%) | 0.662   |
|            | M1   | 4 (2.34%) | 3 (3.45%) | 1 (1.19%) |         |
|            | Unknown | 90 (52.63%) | 45 (51.72%) | 45 (53.57%) |         |
| N          | N0   | 47 (27.49%) | 19 (21.84%) | 28 (33.33%) | 0.1155  |
|            | N1-3 | 119 (69.59%) | 66 (75.86%) | 53 (63.1%) |         |

### TABLE 2 Univariate Cox proportional hazard regression analysis identified 22 DE IncRNAs that are significantly associated with the overall survival of pancreatic cancer patients.

| IncRNA     | Hazard Ratio | P Value |
|------------|--------------|---------|
| PRDM16-DT  | 0.72247472   | 0.01877915 |
| BX640514.2 | 1.31449287   | 0.00069123 |
| AC080969.1 | 0.29543606   | 0.03292011 |
| LINC00996  | 0.30959956   | 0.04539756 |
| AL121929.3 | 0.61423882   | 0.0292435  |
| AC120049.1 | 0.2466323    | 0.01804794 |
| LINC02716  | 0.17449104   | 0.04209901 |
| LINC02577  | 1.35591727   | 0.0475554  |
| AC132938.2 | 0.23067713   | 0.0080087  |
| SOCS2-AS1  | 0.22994143   | 0.0224125  |
| TM4SF1-AS1 | 1.45664584   | 0.00014889 |
| AL355803.1 | 0.39840085   | 0.02972008 |
| AP000892.3 | 0.35860049   | 0.01728944 |
| LINC01133  | 1.0190993    | 0.00016229 |
| AP000757.2 | 0.7841922    | 0.02385144 |
| LINC02041  | 1.13331718   | 0.00108553 |
| AC087752.3 | 0.28291938   | 0.04381474 |
| AL359504.1 | 0.1520814    | 0.00430568 |
| AC104695.4 | 1.12588936   | 0.04270116 |
| CASC8      | 1.2432148    | 0.00063661 |
| SH3PD2A-AS1 | 1.1224769   | 0.03158918 |
| AGI5911.3  | 0.3222307    | 0.03580903 |
We compared the proportion of patients with KRAS mutation within the high-risk and low-risk groups, and as can be seen in Figure 4A, high-risk groups occupied a higher percentage of patients with KRAS mutation compared with low-risk groups in the training set, testing set, and combined TCGA set. Next, we categorized patients from the TCGA set into four different subgroups based on their KRAS mutation status and GILncSig risk group membership. In other words, the following four groups were classified: KRAS Mutation/GU-like group, KRAS Mutation/GS-like group, KRAS Wild/GU-like group and KRAS Wild/GS-like group. Since there was only 1 patient who belonged to the KRAS Mutation/GS-like group, this group was removed from the following analysis. Later, survival analysis was performed. As can be inferred from Figure 4B, the survival outcome was significantly different among these three groups (P = 0.015). KRAS Mutation/GU-like group was predicted to have the worst outcome (median survival time: 1.46 years, 3-year survival rate: 28.0%), KRAS Wild/GS-like group was predicted to have the best outcome (3-year survival rate: 61.2%), whereas KRAS Wild/GU-like group was in between (median survival time: 1.72 years, 3-year survival rate: 28.7%). Our data indicated that GILncSig is able to identify a subpopulation of pancreatic cancer patients who might be at a higher mortality rate and thus deserve a more radical treatment regimen that could otherwise go unnoticed due to their KRAS wild type status. Results for other pancreatic cancer-associated mutated genes were also consistent with KRAS, and results for TP53 are presented in Supplementary Figure 3. Therefore, we believe GILncSig can be an asset to the current literature field of prognostic pancreatic cancer biomarkers.

3.4 Performance comparison of GILncSig with existing IncRNA-related signatures in survival prediction

Finally, we compared the prediction performance of GILncSig with two recently published IncRNA signatures: 3-IncRNA signature obtained from Wu’s study (hereinafter referred as WuLncSig) (38) and 3-IncRNA signature derived from Shi’s study (hereinafter referred as ShiLncSig) (39) using our TCGA patient cohort. As shown in Figure 4C, the AUC at 3 years of OS for our GILncSig is 0.721, which is significantly higher than that of WuLncSig (AUC 0.573) and ShiLncSig (AUC 0.621) in the same patient cohort.

### Table 3

| IncRNA     | Coefficient | Hazard ratio | P value |
|------------|-------------|--------------|---------|
| PRDM16-DT  | -0.2782435  | 0.75711245   | 0.05078589 |
| LINC00996  | -1.1024105  | 0.33206967   | 0.09393344 |
| TM4SF1-AS1 | 0.2916795   | 1.33867397   | 0.00544925 |
| AP000892.3 | -1.042062   | 0.35272661   | 0.02984887 |
| CASC8      | 0.16646916  | 1.18112711   | 0.02519788 |

3.3 GILncSig adds value to the current literature field of prognostic pancreatic cancer biomarker

To investigate whether GILncSig can stand as a solid prognostic biomarker for pancreatic cancer, we tested its correlation with some mutated genes in pancreatic cancer and compared their survival outcome predicting capability. KRAS is a classic oncogene that is actively involved in the pathogenesis of pancreatic cancer (35–37). In addition, growing evidence revealed that KRAS is firmly implicated in the diagnosis and prognosis of pancreatic cancer and is heralded as a potential therapeutic target (35, 37). First of all,
FIGURE 2
Outcome prediction of constructed GILncSig and verification as a valid prognostic factor independent of key clinical features. (A), (C), (E) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in the training set, testing set and the combined TCGA cohort, respectively. Statistical analysis was performed using the log-rank test. (B), (D), (F) Time-dependent ROC curve analysis of GILncSig at 3 years in the training set, testing set and the combined TCGA cohort. (G) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in young-patient group (age ≤ 65). (H) Kaplan-Meier estimates of overall survival predicted by GILncSig for low-risk or high-risk patients in old-patient group.
higher than WuLncSig (AUC = 0.639) and significantly higher than ShiLncSig as well (AUC = 0.651). Even though both WuLncSig and ShiLncSig used a smaller number of lncRNAs (n = 3) than GILncSig (n = 5), we still maintained that our signature should be considered the better model since it can offer a more accurate prediction.

3.5 Functional regulation of GILncSig in pancreatic cancer is potentially associated with EMT and lack of adaptive immunity participation within the TME

3.5.1 Clustering analysis of TCGA dataset yields three different clusters of pancreatic cancer patients

To further understand the potential functional regulatory effects of GILncSig, an explorational graph-based clustering analysis was performed for the whole TCGA dataset. As a result, three distinct clusters were identified among all pancreatic cancer patients and projected onto the UMAP coordinate shown in Figure 5A. The clusters were labeled as cluster 0, cluster 1, and cluster 2 respectively. Top 50 differentially expressed genes and top 30 differentially expressed transcription factors for each cluster were extracted and shown in the heatmaps (Figures 5B, C).

3.5.2 Cluster 1 is associated with EMT

Via close examination of the differentially expressed genes and transcription factors derived from each cluster, it can be inferred that cluster 1 is related to EMT, as SNAI2 and ZBED2, which are pivotal EMT-inducing transcription factors, are differentially upregulated within cluster 1 (40, 41). To further confirm this association, we carried out a gene set enrichment analysis using two EMT signatures from previous literature (32, 42). As shown in Figure 5D, patients’ enriched-ness in expression of genes within each gene set were defined by a signature score calculated through R VISION package. We observed that patients highly enriched for each gene set (whose signature score is ranked at 95th percentile or above) all belonged to cluster 1, further statistical comparison also consolidated that those patients of cluster 1 have the highest EMT signature score (Figure 5E).

3.5.3 GILncSig is associated with EMT

To explore the relationship between GILncSig and the identified clusters, we performed survival analysis for these three clusters and compared their GILncSig risk score levels. As shown in Figure 6A, patients from cluster 1 have the worst prognosis, whereas patients from cluster 0 have the best prognosis. Interestingly, the survival outcome of the patients from these three clusters corresponds tightly to their GILncSig risk score levels, with patients belonging to cluster 1 having the highest GILncSig risk score and patients belonging to cluster 0 harboring the lowest GILncSig risk score (Figure 6B). Furthermore, Pearson correlation analysis showed that the GILncSig risk score is significantly positively associated with EMT signature scores (Figure 6C). Together, these data indicate that pancreatic cancer patients with high GILncSig risk score are more likely to undergo EMT within the tumor, which in return may confer them a worse survival outcome.

3.5.4 TME estimation revealed inadequacy of adaptive immunity participation within GILncSig high-risk group

Finally, we conducted TME estimation using the CIBERSORT algorithm to understand the GILncSig-related immune landscape. Statistical comparison of the concentration of 22 immune cell types within the TME revealed a strikingly diminished adaptive immunity participation in the GILncSig high-risk group. As can be seen from Figures 7A, B, the concentration of naive B cells, activated CD4+ memory T cells and CD8+ T cells were significantly reduced in the GILncSig high-risk group. This observation is further affirmed by the Pearson correlation analysis, which showed that the ImmuneScore is significantly inversely correlated with GILncSig risk score, while T cell exclusion score is significantly positively correlated with GILncSig risk score (Figures 7C, D). Together, these data suggest that the worse survival outcome of pancreatic cancer patients from the GILncSig high-risk group might be in part attributed to the inadequacy of robust adaptive immune cells, i.e., B cell and T cell infiltration within the TME.

---

**TABLE 4** Univariate Cox proportional hazard regression analysis revealed that GILncSig risk score, age and grade are significant prognostic factors.

| Variables            | Hazard ratio | P value |
|----------------------|--------------|---------|
| Age                  | 1.02720658   | 0.01218871 |
| Gender               | 0.87372328   | 0.52335853 |
| Grade                | 1.39198899   | 0.02575897 |
| Stage                | 1.36518243   | 0.105923  |
| GILncSig risk score  | 1.01201713   | 0.01771823 |

**TABLE 5** Multivariate Cox proportional hazard regression analysis using GILncSig risk score, age and grade showed that only GILncSig risk score and age retained their prognostic significance.

| Variables            | Hazard ratio | P value |
|----------------------|--------------|---------|
| Age                  | 1.02728148   | 0.0151126 |
| Grade                | 1.3172337    | 0.06937243 |
| GILncSig risk score  | 1.01540857   | 0.00362892 |

---
In summary, our data provide evidence that the aberrant expression pattern of GILncSig in pancreatic cancer patients can lead to a more invasive cancer subtype, thereby rendering them a worse survival prognosis. This may be achieved through the regulation of genes promoting EMT and the hindrance of adaptive immune cell infiltration within the TME.

3.6 Validation of lncRNA signature by real-time quantitative PCR

The expression levels of all lncRNAs and their target genes in five pancreatic ductal adenocarcinoma tissues and matched normal tissues were detected using qRT-PCR. Compared with
adjacent normal pancreas, the mRNA expression of TM4SF1-AS1 and CASC8 was higher, while the expression of PRDM16-DT (P<0.05), AP000892.3 (P<0.05), and LINC00996 was lower in PDAC tissues (Figure 8A). The expression trend of target genes was consistent with that of lncRNAs (Figure 8B). The results of our validation were consistent with the model, but the statistics of most of the lncRNAs did not show significance due to the large difference in cancer tissues among different individuals.

4 Discussion

Here, we established a computational framework for the identification of genomic instability-related lncRNAs, through which 206 lncRNAs associated with genomic instability were identified, and five lncRNAs (TM4SF1-AS1, CASC8, PRDM16-DT, LINC00996, AP000892.3) were selected from them as independent prognostic factors for constructing GILncSig. It has been found that mutations in key genes or aberrant signaling pathways drive the pathogenesis of PDAC, such as the mutation of oncogene KRAS and the frequent inactivation of tumor suppressors including TP53, SMAD4, and CDKN2A. Moreover, these gene mutations converge in KRAS, TGF-β, Wnt, Notch, and ROBO/SLIT sigaling pathways as well as chromatin remodeling, DNA repair and other pathways and processes (43). This suggests that the high heterogeneity of PDAC is achieved by the overactivation of many signaling pathways related to growth and proliferation and the alteration of the expression levels of tumor suppressor genes, thereby affecting

![FIGURE 4](https://example.com/figure4.png)
cell proliferation, survival and invasion. KRAS mutations, on the other hand, are considered the earliest event in PDAC initiation (44). Therefore, we compared the predictive ability of GILncSig with KRAS for survival outcome and found that GILncSig was able to identify pancreatic cancer patients with KRAS mutations who may have a higher mortality rate than the rest of the patients. Studies have pointed out that the different subtypes defined by gene expression patterns and
clinical features of patients with pancreatic cancer may be of great value in predicting the prognosis of patients and guiding precision medicine (45). In addition, three of the five selected lncRNAs associated with genomic instability (PRDM16-DT, LINC00996, AP000892.3) were protective factors, while TM4SF1-AS1 and CASC8 often served as risk factors associated with poor prognosis (46–50). These lncRNAs have been demonstrated to play an important role in the occurrence, development, and prognosis of a variety of malignant tumors (51–53). However, most of them were found to be associated with the prognosis of PDAC for the first time. Notably, CASC8 is not only strongly associated with poor survival in pancreatic ductal adenocarcinoma, but may also be involved in the process of EMT by competitively binding miR-671 (54).

EMT is a complex biological trans-differentiation process that allows epithelial cells to transiently acquire mesenchymal features, including motility and metastatic potential (55, 56). Activation of EMT is thought to be a major driver of tumor progression from initiation to metastasis. For instance, the EMT transcription factor Zeb1 is not only a key factor in lesion formation, invasion and significant metastasis, but also can affect the stemness and colonization ability of tumor cells, especially phenotypic/metabolic plasticity (55). Further studies revealed that lncRNA Linc-ROR can promote tumor invasion and metastasis by regulating Zeb1 (57). Besides, Zhu, W. et al. 
FIGURE 7
GILncSig associated tumor microenvironment (TME) assessment. (A) Radial plot highlighting the differences of the median proportion of 22 immune cell types in the TME of PDAC patients in the high-risk and low-risk groups. (B) Statistical comparison of the fraction of 22 immune cell types in the TME of patients in the high-risk and low-risk groups assigned based on GILncSig. Red represents the high-risk group and green represents the low-risk group. (C) Pearson correlation analysis between Immune Score and GILncSig risk score. (D) Pearson correlation analysis between T cell exclusion score and GILncSig risk score. *P< 0.05; **P< 0.01; ***P< 0.001.
found that overexpression of lncRNA-CASC8 resulted in up-regulation of TOB1 and low expression of miR-129-5p, which were associated with an increased frequency of lymph node metastasis and a higher trend of pathological stage, respectively, thus validating the CASC8-miR-129-5p-TOB1 regulatory axis (58). These studies all suggested the association of GILncSig with EMT, which we also confirmed in the present study.

The tumor microenvironment of PDAC contains immune components such as interstitial cells, inflammatory cells, and cytokines, which comprise a complex network to promote tumor growth and invasion. It has also been shown that the TME of PDAC is closely related to EMT as well as KRAS (24, 59). So, we used CIBERSORT and estimation algorithms to analyze the details of GILncSig-associated TME profiles, including the estimated proportion of tumor-infiltrating immune cells (TICs) and the quantification of adaptive immune cell exclusion level. The results showed that naïve B cells, activated CD4+ memory T cells, and CD8+ T cell concentrations were significantly lower in the high-risk group. The immune score and T cell exclusion score were significantly negatively and
positively correlated with the GILncSig risk score, respectively, suggesting that this model can predict the degree of infiltration of immune cells. It has been found that reduced infiltration of these adaptive immune cells is associated with the development of pancreatic cancer armed with immune evasion mechanisms and may also impair the effect of immunotherapy in patients (60–63). Therefore, we believe that the treatment of patients can be better guided with the help of this model, especially in the responsiveness of immunotherapy. To our knowledge, this is the first and most comprehensive study to date describing the prognostic and immunotherapeutic response predictive value of TME in patients with PDAC.

Although our study provides important insights for evaluating genomic instability and the prognosis of patients with pancreatic ductal adenocarcinoma, and reveals the association of GILncSig with PDAC immune profiles, there are still some limitations. First, the TCGA cohort containing 171 patients was relatively smaller than the cohort of patients with other cancer types such as breast or lung cancer. In addition, GILncSig was validated only in the TCGA dataset and in five patient specimens due to the lack of a reliable large independent dataset. These shortcomings can only be remedied by further development of these public databases in the future. Second, we need further functional studies to understand the exact regulatory mechanism of GILncSig in maintaining genomic instability. Similarly, the GILncSig-associated tumor microenvironment is achieved by bioinformatics methods, so the results may require more in-depth studies to confirm. Third, there is no data on immunotherapy in the TCGA dataset, so the predictive power of GILncSig for the responsiveness to immunotherapy is indirectly assessed.

In conclusion, we identified lncRNAs associated with genomic instability through a computational framework based on the mutant hypothesis in the present study. By combining lncRNA expression profiles, somatic mutation profiles, and clinical information of pancreatic cancers as case studies, we identified a genomic instability-derived lncRNA signature as an independent prognostic marker to stratify pancreatic cancer patients at risk and validated it in the TCGA cohort. In addition, we used CIBERSORT and estimation algorithms to comprehensively understand the tumor microenvironment in pancreatic cancer patients. Lastly, through the functional enrichment analysis of a distinct cluster of PDAC patients with high GILncSig scores and worse survival prognosis, we found that the distraught expression of genes that promote EMT and prevent adaptive immune cell infiltration in the TME may be the key down-stream regulatory network for GILncSig.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

This study was approved by the local Ethics Committee (Second Xiangya Hospital Ethics Committee) (approved no. 2020–465). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

HY and WZ conceived the study and wrote the manuscript. LX and JH collected the information of patients with pancreatic ductal adenocarcinoma from public databases. JD and WZ performed statistical analysis as well as functional enrichment analysis of the data. YS and HY collected tissue specimens from PDAC patients and completed the validation of GILncSig. ZM, ZS, WP, and YC modified the methods, expressions, and contents in the study, respectively. YX and ZS are responsible for all aspects of the work to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Key Research and Development Program (2018YFE0114500 to YX), the National Science Foundation of Hunan Province for Excellent Young Scholars (2020J3056 to YX), the National Natural Science Foundation of China (NSFC) grant (81870577 to YX), the Natural Science Foundation of Hunan Province for Youths (2022J40718 to LX), the Natural Science Foundation of Changsha (kq2202404 to JH), and the Natural Science Foundation of Hunan Province for Youths (2022J40689 to JH).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those
of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Mariaslan LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res (2014) 74 (11):2931–21. doi: 10.1158/0008-5472.CAN-14-0155

2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology (2020) 159(1):335–49.e135. doi: 10.1053/j.gastro.2020.02.068

3. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol (2019) 16(11):1–26. doi: 10.1038/s41571-018-0111-2

4. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol (2015) 12(6):319–34. doi: 10.1038/nrclinonc.2015.53

5. Hidalgo M. Pancreatic cancer. N Engl J Med (2010) 362(7):1605–17. doi: 10.1056/NEJMra0901557

6. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Commun (2016) 22(2):1342–50. doi: 10.1038/ncomms11169

7. Pilié PG, Tang C, Mills GB, Yap T.A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol (2019) 16(2):81–104. doi: 10.1038/s41571-018-0114-x

8. Liu H. Linking IncRNA to genomic stability. Sci China Life Sci (2016) 59 (3):328–9. doi: 10.1007/s11427-016-0099-6

9. Munschauer M, Nguyen CT, Siromkan K, Hartigan CR, Hogestyn L, Engreitz JM, et al. The NORAD IncRNA assembles a topoisomerase complex critical for genome stability. Nature (2018) 561(7721):132–6. doi: 10.1038/s41586-018-0453-z

10. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, et al. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer (2009) 124(7):1552–64. doi: 10.1002/ijc.24017

11. Zhang S, Yuan Y, Hao D. A genomic instability score in discriminating its manufacturer, is not guaranteed or endorsed by the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.970588/full#supplementary-material

19. Li N, Yang G, Luo L, Ling L, Wang X, Shi L, et al. IncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR-484 and interacting with YAP. Clin Cancer Res (2020) 26(7):1736–48. doi: 10.1158/1078-0432.CCR-19-0974

20. Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J. An immune-related six- IncRNA signature to improve prognosis prediction of glioblastoma multiforme. Mol Neurobiol (2018) 55(5):3684–97. doi: 10.1007/s12035-017-0572-z in pancreatic ductal adenocarcinoma.

21. Ma B, Li Y, Ren Y. Identification of a 6-incRNA prognostic signature based on microarray re-annotation in gastric cancer. Cancer Med (2020) 9(1):335–49. doi: 10.1002/cam4.2621

22. Shen Y, Peng X, Shen C. Identification and validation of immune-related IncRNA prognostic signature for breast cancer. Genomics (2020) 112(3):2640–6. doi: 10.1016/j.ygeno.2020.02.015

23. Bagchi S, Yuan R, Engelen EG. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu Rev Pathol (2021) 16:223–49. doi: 10.1146/annurev-pathol-042020-042741

24. Ren B, Cui M, Yang G, Wang H, Meng F, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer (2018) 17(1):108. doi: 10.1186/s12943-018-0885-1

25. Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell (2019) 178(1):60–75.e127. doi: 10.1016/j.cell.2019.05.012

26. Ho WJ, Jaffe EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol (2020) 17 (9):527–40. doi: 10.1038/s41571-020-0363-5

27. Stromnes JM, Hubbert A, Pierce RH, Greenberg PD, Hingorani SR. T-Cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol Res (2017) 5(11):978–91. doi: 10.1158/2326-6066.CIR-16-0322

28. Feng J, Sun BP, Chen CY, Zhou JY, Chen YS, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res (2019) 29(9):725–38. doi: 10.1042/cnr2019-0195-y

29. Bao S, Zhao H, Yuan J, Fan D, Zhang Z, Su J, et al. Computational identification of mutant-derived IncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer. Brief Bioinform (2020) 21(5):1742–55. doi: 10.1093/bib/bbaa118

30. Zhou Y, Zou B, Pache L,Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun (2019) 10(1):1523. doi: 10.1038/s41467-019-09234-6

31. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res (2013) 5:187–95. doi: 10.2147/camr.s535171

32. Jung AR, Jung CH, Noh JK, Lee YC, Eun YG. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Sci Rep (2020) 10 (1):3652. doi: 10.1038/s41598-020-60707-x

33. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 12 (5):453–7. doi: 10.1038/nmeth.3537

34. Yoshikawa K, Shamorogadoli M, Martinez E, Vegesna R, Kim H, Torres-Wright W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 4:2612. doi: 10.1038/ncomms3612

35. Waters AM, Der CJ. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med (2018) 8(9):656–70. doi: 10.1101/cpmed.001435

36. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 144(6):1220–9. doi: 10.1053/j.gastro.2013.01.071
RNA signature to predict disease-free survival for ovarian cancer patients. Nat Rev Gastroenterol Hepatol (2020) 17(3):153–68. doi: 10.1038/s41575-019-0245-4

86. Wu B, Wang K, Fei J, Bao Y, Wang X, Song Z, et al. Novel three-IncRNA signature predicts survival in patients with pancreatic cancer. Oncol Rep (2018) 40(6):12189–98. doi: 10.3892/or.2018.7541

87. Shi X, Zhao Y, He R, Zhou M, Pan S, Yu S, et al. Three-IncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Oncotarget (2018) 9(36):24248–59. doi: 10.18632/oncotarget.24443

88. Ganesan R, Mallets E, Gomez-Cambronero J. The transcription factors slug (SNAI2) and snail (SNAI1) regulate phospholipase d (PLD) promoter in opposite ways towards cancer cell invasion. Mol Oncol (2016) 10(3):663–76. doi: 10.1016/j.molonc.2015.12.006

89. Somervile TDD, Xu Y, Wu XS, Maia-Silva D, Huir SK, de Almeida LMN, et al. ZBED2 is an antagonist of interferon regulatory factor 1 and modiﬁes cancer cell proliferation of retinoblastoma cells through downregulating miR34a methylation. Cancer Manag Res (2020) 12:13461–7. doi: 10.2147/CMAR.S268380

90. Zhou S, Fang J, Sun Y, Li H. Integrated analysis of a risk score system predicting prognosis and a eRNAs network for differentially expressed IncRNAs in multiple myeloma. Front Genet (2020) 11:934. doi: 10.3389/fgen.2020.00934

91. Wang Y, Yang Y, Wang Y, Li X, Xiao Y, Wang W. High cancer susceptibility candidate 8 expression is associated with poor prognosis of pancreatic adenocarcinoma: Validated analysis based on four cancer databases. Front Cell Dev Biol (2020) 8:392. doi: 10.3389/fcell.2020.00392

92. Krebs AM, Mitschke J, Lasierri Lasoda M, Schmalhofer O, Boerries M, Busch H, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol (2019) 17(3):518–29. doi: 10.1038/ncl.2019.5

93. Saitoh M. Involvement of partial EMT in cancer progression. J Biochem (2018) 164(4):257–64. doi: 10.1093/jb/mmy047

94. Zhan HX, Wang Y, Li C, Xu JW, Zhou B, Zhu JK, et al. LncRNA-ROE promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Cancer Lett (2016) 374(2):261–71. doi: 10.1016/j.canlet.2016.02.018

95. Zhou W, Gao W, Deng Y, Yu X, Zhu H. Identiﬁcation and development of long non-coding RNA associated regulatory network in pancreatic adenocarcinoma. Onco Targets Ther (2020) 13:12083–96. doi: 10.2147/OTT.S265036

96. Yang B, Gu B, Zhang J, Xu L, Sun Y. CASC8 lncRNA promotes the invasion and migration of A549 cells. Mol Oncol (2016) 10(5):663

97. Hsu P, Kapoor A, Zhang Q, Li J, Wu CJ, Li J, et al. Tumor microenvironment remodeling enables bypass of oncofetal KRAS dependency in pancreatic cancer. Cancer Discov (2020) 10(7):1058–77. doi: 10.1158/2159-8290.CD-19-0597

98. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell inﬁltration and response to immunotherapy. Immunity (2018) 49(1):178–93.e177. doi: 10.1016/j.immuni.2018.06.006

99. Das S, Shapiro B, Vucic IA, Vogt S, Bar-Sagi D. Tumor cell-derived IL-1b promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res (2020) 80(5):1088–101. doi: 10.1158/0008-5472.CAN-19-2080

100. Mulekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, et al. B cell-derived IL-35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic cancer. Cancer Immunol Res (2020) 8(3):292–308. doi: 10.1158/2326-6066.CIR-19-0349

101. Takahashi R, Macchini M, Sunagawa M, Jiang Z, Tanaka T, Valenti G, et al. Interleukin-1β-induced pancreatic inflammasome promotes pancreatic ductal adenocarcinoma via b lymphocyte-mediated immune suppression. Gut (2021) 70(2):330–41. doi: 10.1136/gutjnl-2019-319912